Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of liver diseases, primarily non-alcoholic steatohepatitis (NASH) and related conditions

The company’s lead product candidate aims to address the unmet medical needs of patients suffering from these chronic diseases by targeting the underlying mechanisms of liver damage and fibrosis. Through innovative research and development, Galmed is committed to advancing its pipeline of therapeutic solutions to improve patient outcomes and contribute to the evolving landscape of liver disease management.